BioSig Technologies, Inc.(BSGM)

Description: BioSig Technologies is a medical device company developing a proprietary biomedical signal processing technology designed to improve the $4.6 billion electrophysiology (EP) marketplace (www.biosigtech.com). Led by a proven management team and a veteran, independent Board of Directors, Los Angeles-based BioSig Technologies is preparing to commercialize its PURE EP(TM) System. The technology has been developed to address an unmet need in a large and growing market. The Company’s first product, PURE EP(TM) System, is a novel cardiac signal acquisition and display system which is engineered to assist electrophysiologists in clinical decision making during procedures to diagnose and treat patients with abnormal heart rates and rhythms. BioSig’s main goal is to deliver technology to improve upon catheter ablation treatments for the prevalent and potentially deadly arrhythmias: Atrial Fibrillation and Ventricular Tachycardia. BioSig has partnered with Minnetronix on technology development and received FDA 510(k) clearance for the PURE EP(TM) System in August 2018.

---

Keywords: Technology Development Catheter FDA Circulatory System Cardiac Electrophysiology Signal Processing Physiology Ablation Cardiovascular System Arrhythmia Electrophysiology Processing Technology Atrial Fibrillation Cardiac Arrhythmia Catheter Ablation Clinical Cardiac Electrophysiology Heart Arrhythmia Tachycardia Ventricular Tachycardia

---

Home Page: www.biosig.com

BSGM Technical Analysis

55 Greens Farms Road
Westport, CT 06880
United States
Phone: 203 409 5444

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)